Lv5
894 积分 2021-10-19 加入
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
5分钟前
求助中
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
9分钟前
已完结
The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis
57分钟前
已完结
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
1小时前
已完结
Cardiovascular outcomes of SGLT-2 inhibitors’ subtypes in type 2 diabetes; an updated systematic review and meta-analysis of randomized controlled trials
5天前
已完结
Glycemic Improvement with a Fixed‐dose combination of DPP ‐4 inhibitor + metformin in patients with Type 2 diabetes ( GIFT study)
7天前
已完结
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
16天前
已完结
Surgical choice of proximal gastric cancer in China: a retrospective study of a 30-year experience from a single center in China
30天前
已完结
Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway
30天前
已完结
Real‐life implementation of guideline‐recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE‐HF
1个月前
已完结
皖公网安备34019202002308
